NCT07386392Not yet recruiting
Effect of Hypnosis and Virtual Reality on Anxiety During Treatment for Acute Myeloid Leukemia
Effect of Medical Hypnosis Compared to Virtual Reality or Standard Care on Anxiety During Induction Treatment for Acute Myeloid Leukemia
Source: ClinicalTrials.gov · Last updated 4 Feb 2026
Brief summary (registry, in English)
This is a pilot study comparing 3 arms (standard care with hypnosis / standard care with virtual reality / standard care alone), aimed at measuring the effect on anxiety during the induction treatment. Acute myeloid leukemia is considered an oncological emergency that requires chemotherapy treatment with a high risk of serious adverse effects due to prolonged bone marrow failure or drug toxicity. This situation is very stressful for patients, who must cope with the initial symptoms, the diagnosis of a serious cancer, an urgent hospitalization (sometimes in intensive care) and prolonged hospitalization, invasive procedures for diagnosis and initiation of treatment, and intensive chemotherapy requiring protective isolation to contain the risk of life-threatening infection. Added to this care context is the breakdown of family ties as well as socio-professional ties, generating major anxiety and a risk of post-traumatic stress disorder (symptoms, which are common in acute myeloid leukemia. The hypothesis of our study is that hypnosis and virtual reality sessions combined with standard care could reduce anxiety and enhance chemotherapy treatment in acute myeloid leukemia patients when they first learn of their diagnosis.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 99 (estimated)
- First submitted
- 26 Jan 2026
- Start date
- 1 Feb 2026
- Primary completion date
- 31 Mar 2026
- Lead sponsor
- University Hospital, Toulouse
- Diseases
- Acute myeloid leukemia
- NCT number
- NCT07386392
What you commit to
- Study type: Interventional
- Planned participants: 99
- From 1 Feb 2026 to the primary completion date, 31 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who were treated in intensive care prior to hospitalization for induction therapy or following induction therapy
Other illness
- Patients with a diagnosed chronic pain-inducing disease (e.g., rheumatoid arthritis), if not stable
- Patients suffering from epilepsy, whether treated or not, or with a history of epilepsy
Other
- Patients diagnosed with acute myeloid leukemia 3
- Patients with a confirmed diagnosis of psychopathology such as psychosis, depression, or burnout, if not stable
- Patients under guardianship, conservatorship, or legal protection
- Pregnant or breastfeeding women
Who the study is looking for
- Patient over the age of 18
- Patient diagnosed with acute myeloid leukemia in Western Occitanie
- Eligible for first-line induction chemotherapy with anthracycline and cytarabine
- Patient able to understand and respond to a self-administered questionnaire
- Affiliated with or beneficiary of a social security system
- Having signed the research consent form
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IUCT Oncopôle Coordinator of this site? Confirm its status | Toulouse | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.